9 results about "Aminophylline" patented technology

The present application relates to the field of animal reproduction, and discloses a method for improving the efficiency of in vivo oocyte collection of dairy goats by using aminophylline, which comprises the following steps: step one, superovulation treatment of dairy goats, (1) placing a vaginal suppository; (2) orally administering aminophylline; (3) injecting follicle stimulating hormone (FSH); step two, an in vivo oocyte collection operation method (LOPU) of dairy goats; step three, in vitro culture of oocytes, in vitro maturation (IVM) of oocytes; in vitro fertilization (IVF); and in vitro culture (IVC) of oocytes.The present application has the advantage that, compared with the prior art, the number of oocytes collected from dairy goats is significantly increased by aminophylline treatment, and the problem of low oocyte collection rate is solved.

The invention relates to a hybridoma cell strain capable of secreting a creatinine monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity to creatinine, and the IC50 value of the monoclonal antibody to the creatinine is 0.277 g / mL and is far lower than the minimum IC50 value in the prior art. The monoclonal antibody provided by the invention has no cross reaction on structural analogues of creatinine, such as histidine, aminophylline, uric acid, uracil, guanine, adenine, cytosine, L-tryptophan, urea and 2-imino-1-imidazolidine acetic acid, and has good specificity, so that the low-concentration creatinine can be accurately detected.

The invention discloses a medicine for treating chronic obstructive pulmonary disease, and belongs to the technical field of medicine. The active ingredient of the medicine is syringin. Experimental results show that syringin can significantly relieve airflow blockage, inhibit airway inflammation and improve lung tissue injury. More importantly, the invention proves that the syringin and aminophylline are combined for use to achieve a synergistic effect. According to the combined treatment scheme, the curative effect can be remarkably improved, and the dosage and toxic and side effects of aminophylline can be remarkably reduced. Therefore, the invention provides a more efficient and safer innovative medicine and a combined medication strategy thereof for COPD treatment, and has important clinical application value.

A pharmaceutical composition in the form of a transdermal patch comprising aminophylline or theophylline for use in the treatment or prevention of a hypomyelinating or a demyelinating disease or condition or a lesion of the peripheral or central nervous system where demyelination occurs. The patch may comprise a matrix layer comprising a matrix polymer, an active ingredient and a permeation enhancer.

The present invention relates to a contour injection composition, and more specifically, is characterized by an injection composition comprising a solvent, aminophylline, procaine, epinephrine, and hyaluronidase, the injection composition comprising, on the basis of the entire composition, 500 to 700 IU units hyaluronidase, and 0.05 to 0.15% (w / v) aminophylline, 0.01 to 0.03% (w / v) procaine, 0.001 to 0.006% (w / v) epinephrine, and the remainder the solvent, wherein the solvent is half saline and distilled water. According to the present invention, the injection composition has excellent fat decomposition and fat destruction effects and cellulite reduction effect, as well as effect in improving a circulation function, thereby reducing subcutaneous fat in a desired area, and having the advantages not only of improving body and facial lines by improving elasticity, but also not causing side effects such as redness, itchiness, swelling, skin depression, and skin sagging.

The invention discloses ambroxol hydrochloride syrup and a preparation process thereof, and belongs to the technical field of pharmaceutical preparations. The ambroxol hydrochloride syrup comprises ambroxol hydrochloride, a stabilizing cosolvent, a sweetening agent, a preservative, a pH regulator, essence and a solvent. Wherein the stable cosolvent is a composition of propylene glycol, meglumine and propylene carbonate, and the sweetening agent is a composition of cane sugar and a functional sweetening agent. The preparation process comprises the steps of low-temperature pretreatment of the main drug and the stable cosolvent, dissolution and mixing of the auxiliary materials, pH adjustment and essence addition, constant-volume filtration, encapsulation and the like. Through the synergistic effect of a composite stable cosolvent system and a specific preparation process, the storage stability of ambroxol hydrochloride is remarkably improved, meanwhile, the taste of the preparation is optimized, the preparation is wide in applicable crowd, the preparation process is simple and controllable, and good clinical application value and industrialization prospects are achieved.

The invention relates to a growth regulator for improving lodging resistance of corn and a preparation method of the growth regulator, and belongs to the technical field of preparation of plant growth regulators. The growth regulator mainly contains 80 to 90 g / L of choline chloride, 6 to 8 g / L of aminophylline, 1.8 to 2.2 g / L of eicosapentaenoic acid, 20 to 25 g / L of sodium methylene dinaphthalene sulfonate, 10 to 15 g / L of a compound bacterium fermentation extract, 18 to 20 mL / L of Tween-80, 18 to 20 g / L of cyclopropylpyrimidinol, 12 to 15 g / L of zinc glycinate, 0.6 to 0.8 g / L of potassium silicate, 0.3 to 0.4 g / L of ammonium molybdate and 8 to 10 g / L of vitamin B1. The growth regulator prepared by the invention can reduce the plant height and the ear position coefficient of corn and increase the stem diameter, so that the receding resistance and the breaking resistance of the corn are improved, and the lodging resistance of the corn is improved.

The invention belongs to the technical field of animal medicine, and particularly relates to a tortoise respiratory tract infection non-irritant nebulization treatment medicine and a using method thereof.The medicine comprises a first round of nebulization medicine and a second round of nebulization medicine, and the first round of nebulization medicine comprises 10 ml of normal saline and 0.2 ml of aminophylline; and the second-round atomized medicine comprises 10ml of normal saline, 50mg of amikacin, 1mg of dexamethasone and 10mg of ribavirin, and is formed by mixing the normal saline, the amikacin, the dexamethasone and the ribavirin. The using method comprises the steps of early-stage preparation, medicine preparation and atomization operation. According to the tortoise respiratory tract infection non-irritant atomization treatment medicine and the using method thereof, staged synergistic treatment is achieved, and the progressive administration logic of spasmolysis and infection resistance is initiated for the first time; a non-irritant formula is adopted, and zero-damage treatment of the respiratory tracts of turtles is achieved for the first time; the atomization box is used for simulating the original environment of the Dabie mountain, the vicious circle of'stress-food refusal-immunity decline 'of the existing turtles is solved, the integration of'treatment and maintenance' is realized through environment simulation and time control, and the healing effect is improved.

This invention discloses a therapeutic drug for chronic obstructive pulmonary disease (COPD), belonging to the field of medical technology. The active ingredient of this drug is syringin. Experimental results show that syringin can significantly alleviate airflow obstruction, inhibit airway inflammation, and improve lung tissue damage. More importantly, this invention demonstrates the synergistic effect of syringin combined with aminophylline. This combined treatment regimen not only significantly improves efficacy but also significantly reduces the dosage and toxic side effects of aminophylline. Therefore, this invention provides a more efficient and safer innovative drug and its combination therapy strategy for COPD treatment, possessing significant clinical application value.